Patents by Inventor Daniel Solomon
Daniel Solomon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190225666Abstract: The present invention relates in general to therapeutic fusion proteins useful to treat lysosomal storage diseases and methods for treating such diseases. Exemplary therapeutic fusion proteins comprise a lysosomal enzyme, a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. Also provided are compositions and methods for treating Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome), comprising a targeted therapeutic fusion protein comprising alpha-N-acetylglucosaminidase (Naglu), a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide.Type: ApplicationFiled: April 8, 2019Publication date: July 25, 2019Inventors: Mika Aoyagi-Scharber, Teresa Margaret Christianson, Melita Dvorak-Ewell, Daniel J. Wendt, Shinong Long, Jonathan LeBowitz, Daniel Solomon Gold
-
Publication number: 20190169557Abstract: A perfusion manifold assembly is described that allows for perfusion of a microfluidic device, such as an organ on a chip microfluidic device comprising cells that mimic cells in an organ in the body, that is detachably linked with said assembly so that fluid enters ports of the microfluidic device from a fluid reservoir, optionally without tubing, at a controllable flow rate. Drop-to-drop connection schemes are described for putting a microfluidic device in fluidic communication with a fluid source or another microfluidic device, including but not limited to, putting a microfluidic device in fluidic communication with the perfusion manifold assembly.Type: ApplicationFiled: December 19, 2018Publication date: June 6, 2019Inventors: Daniel Levner, Josiah Daniel Sliz, Christopher David Hinojosa, Guy Robert Thompson, II, Petrus Wilhelmus Martinus van Ruijven, Matthew Daniel Solomon, Christian Alexander Potzner, Patrick Sean Tuohy, Joshua Gomes, Norman Wen, Jacob Freake, Doug Sabin
-
Patent number: 10301369Abstract: The present invention relates in general to therapeutic fusion proteins useful to treat lysosomal storage diseases and methods for treating such diseases. Exemplary therapeutic fusion proteins comprise a lysosomal enzyme, a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. Also provided are compositions and methods for treating Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome), comprising a targeted therapeutic fusion protein comprising alpha-N-acetylglucosaminidase (Naglu), a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide.Type: GrantFiled: August 28, 2017Date of Patent: May 28, 2019Assignee: BioMarin Pharmaceutical Inc.Inventors: Mika Aoyagi-Scharber, Teresa Margaret Christianson, Melita Dvorak-Ewell, Daniel J. Wendt, Shinong Long, Jonathan LeBowitz, Daniel Solomon Gold
-
Patent number: 10273523Abstract: An assembly for preparing a specimen is provided that may be configured to determine the presence of at least one microorganism specie in the specimen. The assembly may include a pipette configured to acquire a specimen from a sample and an imaging cartridge configured to be in fluid communication with the pipette. The imaging cartridge and the pipette may be configured to be irreversibly coupled such that the specimen is bio-contained within the imaging cartridge and the pipette when the imaging cartridge and pipette are coupled together. Associated methods of use are also provided.Type: GrantFiled: April 28, 2014Date of Patent: April 30, 2019Assignee: Becton, Dickinson and CompanyInventors: Alexander George Lastovich, Anita Quinn, Pauline Elizabeth Bell, James Lee Schram, Rex Young Nielson, Jason Paul Hayes, Matthew James Springer, Lincoln Belcourt, Matthew Daniel Solomon
-
Patent number: 10273441Abstract: The invention relates to a perfusion manifold assembly that allows for perfusion of a microfluidic device, such as an organ on a chip microfluidic device comprising cells that mimic cells in an organ in the body, that is detachably linked with an assembly so that fluid enters ports of the microfluidic device from a fluid reservoir, optionally without tubing, at a controllable flow rate. The invention further relates to a drop-to-drop connection scheme for putting a microfluidic device in fluidic communication with a fluid source or another microfluidic device, including but not limited to, putting a microfluidic device in fluidic communication with the perfusion manifold assembly.Type: GrantFiled: August 26, 2016Date of Patent: April 30, 2019Assignee: EMULATE, Inc.Inventors: Daniel Levner, Josiah Daniel Sliz, Christopher David Hinojosa, Guy Robert Thompson, II, Petrus Wilhelmus Martinus van Ruijven, Matthew Daniel Solomon, Christian Alexander Potzner, Patrick Sean Tuohy, Joshua Gomes, Norman Wen, Jacob Freake, Doug Sabin
-
Publication number: 20190002811Abstract: Drop-to-drop connection schemes are described for putting a microfluidic device in fluidic communication with a fluid source or another microfluidic device, including but not limited to, putting a microfluidic device in fluidic communication with the perfusion manifold assembly.Type: ApplicationFiled: August 22, 2018Publication date: January 3, 2019Inventors: Daniel Levner, Josiah Daniel Sliz, Christopher David Hinojosa, Guy Robert Thompson, II, Petrus Wilhelmus Martinus van Ruijven, Matthew Daniel Solomon, Christian Alexander Potzner, Patrick Sean Tuohy
-
Patent number: 10125342Abstract: Drop-to-drop connection schemes are described for putting a microfluidic device in fluidic communication with a fluid source or another microfluidic device, including but not limited to, putting a microfluidic device in fluidic communication with the perfusion manifold assembly.Type: GrantFiled: August 26, 2016Date of Patent: November 13, 2018Assignee: EMULATE, Inc.Inventors: Daniel Levner, Josiah Daniel Sliz, Christopher David Hinojosa, Guy Robert Thompson, II, Petrus Wilhelmus Martinus van Ruijven, Matthew Daniel Solomon, Christian Alexander Potzner, Patrick Sean Tuohy
-
Patent number: 9845346Abstract: The present invention relates in general to therapeutic fusion proteins useful to treat lysosomal storage diseases and methods for treating such diseases. Exemplary therapeutic fusion proteins comprise a lysosomal enzyme, a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. Also provided are compositions and methods for treating Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome), comprising a targeted therapeutic fusion protein comprising alpha-N-acetylglucosaminidase (Naglu), a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide.Type: GrantFiled: October 14, 2015Date of Patent: December 19, 2017Assignee: BioMarin Pharmaceurical Inc.Inventors: Mika Aoyagi-Scharber, Teresa Margaret Christianson, Melita Dvorak-Ewell, Daniel J. Wendt, Shinong Long, Jonathan LeBowitz, Daniel Solomon Gold
-
Publication number: 20170355744Abstract: The present invention relates in general to therapeutic fusion proteins useful to treat lysosomal storage diseases and methods for treating such diseases. Exemplary therapeutic fusion proteins comprise a lysosomal enzyme, a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. Also provided are compositions and methods for treating Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome), comprising a targeted therapeutic fusion protein comprising alpha-N-acetylglucosaminidase (Naglu), a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide.Type: ApplicationFiled: August 28, 2017Publication date: December 14, 2017Applicant: BIOMARIN PHARMACEUTICAL INC.Inventors: MIKA AOYAGI-SCHARBER, TERESA MARGARET CHRISTIANSON, MELITA DVORAK-EWELL, DANIEL J. WENDT, SHINONG LONG, JONATHAN LeBOWITZ, DANIEL SOLOMON GOLD
-
Patent number: 9834587Abstract: The present invention relates in general to therapeutic fusion proteins useful to treat lysosomal storage diseases and methods for treating such diseases. Exemplary therapeutic fusion proteins comprise a lysosomal enzyme, a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. Also provided are compositions and methods for treating Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome), comprising a targeted therapeutic fusion protein comprising alpha-N-acetylglucosaminidase (Naglu), a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide.Type: GrantFiled: October 14, 2015Date of Patent: December 5, 2017Assignee: BIOMARIN PHARMACEUTICAL INC.Inventors: Mika Aoyagi-Scharber, Teresa Margaret Christianson, Melita Dvorak-Ewell, Daniel J. Wendt, Shinong Long, Jonathan LeBowitz, Daniel Solomon Gold
-
Patent number: 9834588Abstract: The present invention relates in general to therapeutic fusion proteins useful to treat lysosomal storage diseases and methods for treating such diseases. Exemplary therapeutic fusion proteins comprise a lysosomal enzyme, a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. Also provided are compositions and methods for treating Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome), comprising a targeted therapeutic fusion protein comprising alpha-N-acetylglucosaminidase (Naglu), a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide.Type: GrantFiled: October 14, 2015Date of Patent: December 5, 2017Assignee: BIOMARIN PHARMACEUTICAL INC.Inventors: Mika Aoyagi-Scharber, Teresa Margaret Christianson, Melita Dvorak-Ewell, Daniel J. Wendt, Shinong Long, Jonathan LeBowitz, Daniel Solomon Gold
-
Patent number: 9771408Abstract: The present invention relates in general to therapeutic fusion proteins useful to treat lysosomal storage diseases and methods for treating such diseases. Exemplary therapeutic fusion proteins comprise a lysosomal enzyme, a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. Also provided are compositions and methods for treating Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome), comprising a targeted therapeutic fusion protein comprising alpha-N-acetylglucosaminidase (Naglu), a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide.Type: GrantFiled: October 14, 2015Date of Patent: September 26, 2017Assignee: BioMarin Pharmaceutical Inc.Inventors: Mika Aoyagi-Scharber, Teresa Margaret Christianson, Melita Dvorak-Ewell, Daniel J. Wendt, Shinong Long, Jonathan LeBowitz, Daniel Solomon Gold
-
Publication number: 20170248573Abstract: Systems, methods, and devices for analyzing small volumes of fluidic samples, as a non-limiting example, less than twenty microliters are provided. The devices are configured to make a first sample reading, for example, measure an energy property of the fluid sample, for example, osmolality, make a second sample reading, for example, detecting the presence or concentration of one or more analytes in the fluid sample, or make both the first sample reading and the second sample reading, for example, measuring the energy property of the fluid sample as well as detecting the presence or concentration of one or more analytes in the fluid sample.Type: ApplicationFiled: September 23, 2015Publication date: August 31, 2017Inventors: Benjamin SULLIVAN, Steve ZMINA, Melissa LEE, Brandon WESTERBERG, Matthew Daniel SOLOMON, Christian POTZNER, Sebastiaan GARST, Matthew SPRINGER, Jason HAYES, Peter MUNSTER, Erol Craig HARVEY, Michael WILKINSON, Joanna SLOWINSKA, Derek LEE, Peter VAN RUIJVEN
-
Publication number: 20170055522Abstract: A perfusion manifold assembly is described that allows for perfusion of a microfluidic device, such as an organ on a chip microfluidic device comprising cells that mimic cells in an organ in the body, that is detachably linked with said assembly so that fluid enters ports of the microfluidic device from a fluid reservoir, optionally without tubing, at a controllable flow rate. Drop-to-drop connection schemes are described for putting a microfluidic device in fluidic communication with a fluid source or another microfluidic device, including but not limited to, putting a microfluidic device in fluidic communication with the perfusion manifold assembly.Type: ApplicationFiled: August 26, 2016Publication date: March 2, 2017Inventors: Daniel Levner, Josiah Daniel Sliz, Christopher David Hinojosa, Guy Robert Thompson, Petrus Wilhelmus Martinus van Ruijven, Matthew Daniel Solomon, Christian Alexander Potzner, Patrick Sean Tuohy, Joshua Gomes, Norman Wen, Jacob Freake, Doug Sabin
-
Publication number: 20170058243Abstract: Drop-to-drop connection schemes are described for putting a microfluidic device in fluidic communication with a fluid source or another microfluidic device, including but not limited to, putting a microfluidic device in fluidic communication with the perfusion manifold assembly.Type: ApplicationFiled: August 26, 2016Publication date: March 2, 2017Inventors: Daniel Levner, Josiah Daniel Sliz, Christopher David Hinojosa, Guy Robert Thompson, Petrus Wilhelmus Martinus van Ruijven, Matthew Daniel Solomon, Christian Alexander Potzner, Patrick Sean Tuohy
-
Publication number: 20170056880Abstract: Drop-to-drop connection schemes are described for putting a microfluidic device in fluidic communication with a fluid source or another microfluidic device. Methods for establishing fluid connections with guide mechanisms are described.Type: ApplicationFiled: August 26, 2016Publication date: March 2, 2017Inventors: Daniel Levner, Josiah Daniel Sliz, Christopher David Hinojosa, Guy Robert Thompson, Petrus Wilhelmus Martinus van Ruijven, Matthew Daniel Solomon, Christian Alexander Potzner, Patrick Sean Tuohy, Joshua Gomes
-
Patent number: 9376480Abstract: The present invention relates in general to therapeutic fusion proteins useful to treat lysosomal storage diseases and methods for treating such diseases. Exemplary therapeutic fusion proteins comprise a lysosomal enzyme, a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. Also provided are compositions and methods for treating Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome), comprising a targeted therapeutic fusion protein comprising alpha-N-acetylglucosaminidase (Naglu), a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide.Type: GrantFiled: November 27, 2013Date of Patent: June 28, 2016Assignee: BIOMARIN PHARMACEUTICAL INC.Inventors: Mika Aoyagi-Scharber, Teresa Margaret Christianson, Melita Dvorak-Ewell, Daniel J. Wendt, Shinong Long, Jonathan LeBowitz, Daniel Solomon Gold
-
Publication number: 20160076072Abstract: An assembly for preparing a specimen is provided that may be configured to determine the presence of at least one microorganism specie in the specimen. The assembly may include a pipette configured to acquire a specimen from a sample and an imaging cartridge configured to be in fluid communication with the pipette. The imaging cartridge and the pipette may be configured to be irreversibly coupled such that the specimen is bio-contained within the imaging cartridge and the pipette when the imaging cartridge and pipette are coupled together. Associated methods of use are also provided.Type: ApplicationFiled: April 28, 2014Publication date: March 17, 2016Applicant: Becton, Dickinson and CompanyInventors: Alexander George Lastovich, Anita Quinn, Pauline Elizabeth Bell, James Lee Schram, Rex Young Nielson, Jason Paul Hayes, Matthew James Springer, Lincoln Belcourt, Matthew Daniel Solomon
-
Publication number: 20160039900Abstract: The present invention relates in general to therapeutic fusion proteins useful to treat lysosomal storage diseases and methods for treating such diseases. Exemplary therapeutic fusion proteins comprise a lysosomal enzyme, a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. Also provided are compositions and methods for treating Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome), comprising a targeted therapeutic fusion protein comprising alpha-N-acetylglucosaminidase (Naglu), a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide.Type: ApplicationFiled: October 14, 2015Publication date: February 11, 2016Inventors: Mika Aoyagi-Scharber, Teresa Margaret Christianson, Melita Dvorak-Ewell, Daniel J. Wendt, Shinong Long, Jonathan LeBowitz, Daniel Solomon Gold
-
Publication number: 20160031965Abstract: The present invention relates in general to therapeutic fusion proteins useful to treat lysosomal storage diseases and methods for treating such diseases. Exemplary therapeutic fusion proteins comprise a lysosomal enzyme, a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. Also provided are compositions and methods for treating Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome), comprising a targeted therapeutic fusion protein comprising alpha-N-acetylglucosaminidase (Naglu), a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide.Type: ApplicationFiled: October 14, 2015Publication date: February 4, 2016Inventors: Mika Aoyagi-Scharber, Teresa Margaret Christianson, Melita Dvorak-Ewell, Daniel J. Wendt, Shinong Long, Jonathan LeBowitz, Daniel Solomon Gold